Creative Biostructure can provide highly customized virus-like particles (VLPs) in cell targeting to facilitate biology and medicine research and development by our outstanding VLPs technology platform. We also provide first-class services for a variety of VLPs applications.
Figure 1. Preparation of dye-labeled Qβ-EGF virus-like particles. (Chem. Bio. Chem, 2011)
Virus-like particles (VLPs) mimic the whole construct of virus particles devoid of viral genome as used in subunit vaccine design. VLPs can elicit efficient protective immunity as direct immunogens compared to soluble antigens co-administered with adjuvants in several booster injections.The main goal of cell targeting is to uptake the diagnostic reagent and the therapeutic effectively in a special position in vivo such as a tumor, which making virus-like particles valuable as therapeutic modalities because they can not only improve the efficacy of drugs but also reduce adverse effects by concentrating the required therapeutic molecules. By using other molecules such as vitamins, carbohydrates proteins (mainly antibodies), peptides, and nucleic acids (aptamers), we can also achieve cell targeting. Creative Biostructure can give specificity to cell targeting by attaching the targeting ligands to VLPs.
Virus-like particles are of great potentials in cell targeting because we can manipulate the scaffold by both genetical and chemical methods to display targeting groups and carry a functional payload simultaneously. Our advanced VLPs technology has a lot of advantages for cell targeting as follows:
1. Without propagation of pathogenic organisms,
2. Large surface area with ordered structures,
3. More stable in extreme environmental conditions,
4. Ability to display foreign antigens，
5. Repetitive and ordered surface structures，
6. Safer than other vaccines.
Viral-like particles (VLPs) have shown high ability for the improvement of vaccines against infectious and non-infectious diseases. Recently, Simian viruses 40 (SV40) VLPs have drawn a great attention in DNA and siRNA delivery because of their low toxicity and high stability. Creative Biostructure has successfully modified the SV40 VLPs with human epidermal growth factor (EGF) by chemical conjugation, allowing the selective cell targeting. We can also display EGF on bacteriophage Qβ by C-terminal genetic fusion.
We also provide various Mempro™ Virus-like Particles (VLPs) Application services in vaccines, bioimaging, delivery systems, and lipoparticle technology, which are shown in related sections. Please feel free to contact us for a detailed quote.
Z. Shirbaghaee, et al. (2015). Different Applications of Virus-Like Particles in Biology and Medicine: Vaccination and Delivery Systems. Biopolymers, 105(3): 113–132.
J. K. Pokorski, et al. (2011). Cell Targeting with Hybrid Qβ Virus-Like Particles Displaying Epidermal Growth Factor. Chem. Bio. Chem.,12(16): 2441–2447.
I. Yildiz, et al. (2011). Applications of viral nanoparticles in medicine. Curr. Opin. Biotechnol., 22(6): 901-908.
C. E. Ashley, et al. (2011). Cell-Specific Delivery of Diverse Cargos by Bacteriophage MS2 Virus-like Particles. ACS Nano, 5(7): pp 5729–5745.